The patent application describes an ex - vivo method of increasing survival of red blood cells (RBCs). The method comprises contacting the RBCs with an activator of the non - canonical Wnt pathway, which results in actin polymerization, thereby increasing survival of RBCs. The invention's description states "The Haemolysates were enriched with over 95 % hemoglobin. For hemoglobin depletion, the hemoglobin depletion kit of HemoVoid … was used". Upon depletion of hemoglobin, a reduction in cytoplasmic actin levels was observed. Also the patent application describes a method of storing RBCs and treating a medical condition associated with RBC cytoskeleton / membrane disease.

"There is great interest in understanding the proteomic changes in red cells upon storage. As red cells are enucleated, there are no cellular mechanisms to produce new proteins so changes occur at the post-translational level. As this patent application describes, proteomic analysis is a very productive way to uncover those important changes. I am pleased that our HemoVoid™ product was quite useful for that purpose" states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com